# Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

> **NCT04348890** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **ReveraGen BioPharma, Inc.**

## Conditions studied

- Pediatric Ulcerative Colitis

## Interventions

- **DRUG:** Vamorolone 4% suspension for oral dosing

## Key facts

- **NCT ID:** NCT04348890
- **Lead sponsor:** ReveraGen BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Programmatic decision
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348890, "Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04348890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*